Kurs
+0,14%
Kurs
+0,14%
Open
74,00
High
75,00
Low
70,50
Close
73,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
Est. tid* | ||
2026-02-25 | 06:30 | Bokslutskommuniké 2025 |
2025-11-26 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-23 | N/A | X-dag ordinarie utdelning NYKD 0.00 NOK |
2025-05-22 | N/A | Årsstämma |
2025-05-14 | 07:00 | Kvartalsrapport 2025-Q1 |
2025-02-26 | - | Bokslutskommuniké 2024 |
2024-11-27 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2024-05-16 | - | Årsstämma |
2024-05-14 | - | Kvartalsrapport 2024-Q1 |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-15 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2023-05-11 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-23 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-16 | - | Kvartalsrapport 2022-Q1 |
2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2022-05-12 | - | Årsstämma |
2022-03-31 | - | Bokslutskommuniké 2021 |
2021-12-22 | - | Extra Bolagsstämma 2021 |
2021-11-17 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
2021-05-05 | - | Årsstämma |
2021-04-21 | - | Bokslutskommuniké 2020 |
2020-11-17 | - | Kvartalsrapport 2020-Q3 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-07-07 | - | Split NYKD 1:5 |
2020-07-06 | - | Extra Bolagsstämma |
2020-05-12 | - | Kvartalsrapport 2020-Q1 |
2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2021-05-12 08:30:00
Oslo, Norway, May 12, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, today announced its first quarter 2021 results.
The first quarter 2021 report will be available at
https://www.vaccibody.com/financial-reports-and-presentations/
Contact for Vaccibody:
CEO Michael Engsig
Vaccibody AS
info@vaccibody.com
About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung- , head and neck, renal-, and bladder cancer